Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abemaciclib + darolutamide
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a **combination investigational therapy** of two oral small molecule drugs: abemaciclib and darolutamide. **Abemaciclib** is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, which blocks cell cycle progression and inhibits cancer cell proliferation. **Darolutamide** is a nonsteroidal androgen receptor antagonist that prevents androgens (male hormones) from fueling the growth of prostate cancer cells. This drug combination is being studied for synergistic effects in advanced prostate cancer, particularly metastatic and castration-resistant forms, with or without standard androgen deprivation therapy (ADT). The regimen is designed to target distinct pathways in prostate cancer biology: abemaciclib targets cell-cycle regulation while darolutamide disrupts androgen-driven growth. This combination is investigational for prostate cancer and is being evaluated in phase 1 and phase 2 clinical trials for safety and preliminary efficacy[1][2][3][4][5][6].
- Brand names
- Verzenio (abemaciclib)Nubeqa (darolutamide)
- Other names
- abemaciclib + darolutamide
02
Targets
AR (Adrenergic receptors)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on abemaciclib + darolutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abemaciclib + darolutamide.